Transactions
Oct. 31, 2000
Orrick Herrington: MERGING DRUG COMPANIES CREATE POWERFUL TEAM
Corixa Corp. has agreed to acquire all outstanding shares of Coulter Pharmaceutical Inc. The deal is valued in excess of $900 million. Seattle-based Corixa is a biotechnology company focusing on the research and development of immunotherapuetic products that treat autoimmune diseases, cancers and infectious diseases.




Seattle-based Corixa is a biotechnology company focusing on the research and development of immunotherapuetic products that treat autoimmune diseases, cancers and infectious diseases. The company is currently developing vaccines for skin, breast,...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In